Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T; Austrian MS Treatment Registry (AMSTR).
Real-life use of oral disease-modifying treatments in Austria.
Acta Neurol Scand. 2019; 140(1):32-39 Doi: 10.1111/ane.13097 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Enzinger Christian

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

To compare the efficacy, frequencies and reasons for treatment interruption of fingolimod, dimethyl fumarate (DMF) or teriflunomide in a nationwide observational cohort using prospectively collected data. Two cohorts of patients with relapsing-remitting multiple sclerosis (RRMS) starting treatment with fingolimod, dimethyl fumarate or teriflunomide documented in the Austrian MS Treatment Registry (AMSTR) since 2014 and either staying on therapy for at least 12 months (12m cohort) or having at least one follow-up visit (total cohort). The 12m cohort included 664 RRMS patients: 315 in the fingolimod, 232 in the DMF and 117 in the teriflunomide group. Multinomial propensity scores were used for inverse probability weighting to correct for the bias of this non-randomised registry study. Estimated mean annualized relapse rates (ARR) over 12 months were 0.21 for fingolimod, 0.20 for DMF and 0.19 for teriflunomide treatment, causing an incidence rate ratio (IRR) of 1.01 for fingolimod vs DMF (P = 0.96) and 0.92 for teriflunomide vs DMF (P = 0.84). No differences were found regarding the probability for experiencing a relapse, EDSS change, EDSS progression and EDSS regression, except regarding less sustained EDSS progression for 12 weeks concerning DMF vs fingolimod (P = 0.02). The hazard ratio for treatment interruption comparing fingolimod vs DMF was 1.03 (P = 0.86) and 1.07 comparing teriflunomide vs DMF (P = 0.77). In the AMSTR, there was no difference concerning ARR, probability for a relapse, EDSS change, treatment interruption, EDSS progression or regression between oral DMTs, except regarding less sustained EDSS progression for 12 weeks concerning DMF vs fingolimod. © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Find related publications in this database (using NLM MeSH Indexing)
Administration, Oral -
Adult -
Adult -
Cohort Studies -
Crotonates - therapeutic use
Dimethyl Fumarate - therapeutic use
Disease Progression -
Female -
Fingolimod Hydrochloride - therapeutic use
Humans -
Immunosuppressive Agents - therapeutic use
Male -
Middle Aged -
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Propensity Score -
Recurrence -
Registries -
Toluidines - therapeutic use

Find related publications in this database (Keywords)
dimethyl fumarate
inverse probability weighting
multiple sclerosis
propensity score
© Med Uni Graz Impressum